Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876644 | 0.92 | MAPK10 (0.46) | LMNAMAPK10HTR7HCAR2PIM1 | |
| SCHEMBL5877175 | 0.86 | IDO1 (0.45) | LMNAMAPK10HTR7MAPK1PIM1 | |
| SCHEMBL5875946 | 0.83 | ADORA2A (0.38) | LMNAMAPK10HTR7CDK2HCAR2 | |
| SCHEMBL5876901 | 0.82 | LRRK2 (0.40) | LMNAMAPK10HTR7HCAR2PRCP | |
| SCHEMBL5876817 | 0.81 | KDM4E (0.39) | LMNAMAPK10HTR7HCAR2MAPK1 | |
| SCHEMBL5878102 | 0.81 | IDO1 (0.42) | LMNAMAPK10HTR7HCAR2PIM1 | |
| SCHEMBL5875877 | 0.80 | NISCH (0.41) | LMNAMAPK10HTR7CDK2HCAR2 | |
| SCHEMBL5875980 | 0.79 | PDPK1 (0.40) | LMNAMAPK10HTR7HCAR2CDC7 | |
| SCHEMBL5876657 | 0.79 | HDAC4 (0.37) | LMNAMAPK10HTR7HCAR2 | |
| SCHEMBL5877629 | 0.79 | LMNA (0.33) | LMNAMAPK10HTR7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | MKNK1 1340/4885LMNA 4385/4885MAPK10 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.